LAUSR

since we will be able to compare our results with the once published previously. Method: We have reviewed 129 patients with NSCLC, advanced or recurrent stages, treated with nivolCutumab either in second and subsequent lines of treatment, after progression to a platinum-based scheme from its expanded use until April 2018, in five hospitals in Spain. The information was collected retrospectively of clinical, analytical, pathological and treatment characteristics of the patients. Statistical analysis was performed using the SPSS software vs 21.0, considering the statistical significance if p <0.05 Result: With a median follow-up of 6 months (0-31), the overall survival (OS) was 9 months (5.86-12.14).Patients with ECOG 0-1 presented a median OS of 11 months compared to 3 months of median OS in patients with ECOG 2 (p: 0.001)If the response to previous treatment was complete response, partial response or stabilization of the disease, they will have a median OS of 12 months compared to 6 months if the best response was progression (p: 0.002).There is also a statistically significant difference in terms of overall survival in relation to the existence of toxicity for immunotherapy or not (median of 13 versus 6 months p: 0.004).The overall survival of patients who had progressed beyond 6 months after the start of treatment with prior chemotherapy was significantly greater than patients who had progressed in the first 6 months after the start of chemotherapy (median of 4 months versus median of 13 months, p: 0.001) Conclusion: Immunotherapy has come to stay taking part of the usual clinical practice of patients with lung cancer. The results obtained in our population are comparable to those previously published, with an important group of patients that responded to immunotherapy or stabilized even for a long time. However, we highlight that also there is a percentage of patients, who progress early. We see fundamental to find or recognize, not just the ideal biomarker that helps to predict response, but those clinical characteristics that can make us presage a poor result.